Progress in PARP inhibitors beyond BRCA mutant recurrent ovarian cancer?
Mené sur 206 patientes atteintes d'un carcinome ovarien de haut grade sensible aux sels de platine et récidivant, cet essai international de phase II évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité du rucaparib, un inhibiteur de PARP dispensé par voie orale, selon la présence de mutations BRCA ou la perte d'hétérozygotie BRCA
Up to half of newly diagnosed patients with high-grade serous ovarian cancer have a deficit in the homologous recombination system, which repairs double-strand breaks in DNA. Mutations in BRCA1 or BRCA2, which occur in roughly 20% of patients (16% germline and 4% somatic), are the most common cause of homologous recombination deficiency.1 Patients with BRCA mutations have longer overall survival than do patients without such mutations, and their tumours are extremely sensitive to platinum-based chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors.
The Lancet Oncology , commentaire, 2015